Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HILLIER study of benralizumab in moderate to severe atopic dermatitis
2020-000285-42Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Sep 2020; status: completed.
02
Drugs
benralizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2020-000285-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000285-42.